- Report
- June 2024
- 200 Pages
Global
From €5611EUR$6,360USD£4,913GBP
€7014EUR$7,950USD£6,142GBP
- Report
- May 2024
- 134 Pages
Global
From €4874EUR$5,524USD£4,268GBP
€5734EUR$6,499USD£5,021GBP
- Report
- August 2023
- 367 Pages
Global
From €2206EUR$2,500USD£1,931GBP
The Arthralgia Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. It is composed of drugs used to treat arthralgia, which is a type of joint pain. These drugs are typically used to reduce inflammation and pain, and can be administered orally, topically, or through injection. Commonly used drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs).
The Arthralgia Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and AbbVie. Other companies include Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. Show Less Read more